RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Pipeline Review, H2 2018
Summary
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - RAC-gamma serine/threonine-protein kinase is an enzyme encoded by the AKT3 gene. AKT3 regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. It plays an important role in brain development and viability of malignant glioma cells. It is required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands.
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 1 and 1 respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Adenoid Cystic Carcinoma (ACC), Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Orphan Diseases (Rare Diseases), Peritoneal Cancer, Prostate Cancer, Proteus Syndrome, Renal Cell Carcinoma, Sickle Cell Disease, Small-Cell Lung Cancer and Thymoma (Thymic Epithelial Tumor).
The latest report RAC Gamma SerineThreonine Protein Kinase - Pipeline Review, H2 2018, outlays comprehensive information on the RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook